Sublocade (formerly RBP-6000) is an extended-release formulation of buprenorphine intended for the treatment of moderate-to-severe opioid use disorder in patients who have undergone induction with a transmucosal buprenorphine-containing product to suppress opioid withdrawal signs and symptoms. Sublocade utilizes the Atrigel Delivery System, which consists of a biodegradable polymer dissolved in a biocompatible solvent. Sublocade is administered once monthly by subcutaneous (SC) injection in the abdominal region and provides sustained plasma levels of buprenorphine over the dosing interval. Sublocade is injected as a solution and subsequent precipitation of the polymer creates a solid depot containing buprenorphine. Buprenorphine is released via diffusion and biodegradation of the depot.
If you have a Hayes login, click here to view the full report on the Knowledge Center.